Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supernus PharmaceuticalsLTS:0LB2 +0.46%87 EV-to-FCF is 127.79 as of Aug. 15, 2026, which is 760% above its 10-year median of 14.86. GuruFocus rates LTS:0LB2 with a GF Score™ of 87/100 and a GF Value™ of $43.43 (Fairly Valued). The stock has 2 warning signs investors should review. Among 561 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 88.41% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Supernus Pharmaceuticals's Enterprise Value is $2,473.3 Mil.
Supernus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $19.4 Mil. Therefore, Supernus Pharmaceuticals's EV-to-FCF for today is 127.79.
The historical rank and industry rank for Supernus Pharmaceuticals's EV-to-FCF or its related term are showing as below:
LTS:0LB2'
s EV-to-FCF Range Over the Past 10 Years
Min: 6.17 Med: 14.86 Max: 128.24
Current: 127.79
During the past 13 years, the highest EV-to-FCF of Supernus Pharmaceuticals was 128.24. The lowest was 6.17. And the median was 14.86.
LTS:0LB2's EV-to-FCF is ranked worse than 88.41% of 561
companies
in the Drug Manufacturers industry
Industry Median: 21.29
vs LTS:0LB2: 127.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Supernus Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Supernus Pharmaceuticals's share price for today is $47.95.
Supernus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.920.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Supernus Pharmaceuticals EV-to-FCF Related Terms
Supernus Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's EV-to-FCF falls into.
Supernus Pharmaceuticals's current Enterprise Value is $2,473.3 Mil.
Supernus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a EV-to-FCF of 127.79 as of Aug. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Supernus Pharmaceuticals and its competitors. This is 760% above median its historical median of 14.86. Over the past decade, Supernus Pharmaceuticals' EV-to-FCF has ranged from 6.17 to 128.24. According to the industry distribution chart, Supernus Pharmaceuticals ranks #496 out of 561 companies in the Drug Manufacturers industry, placing it in the top 88.4%.
Is Supernus Pharmaceuticals' EV-to-FCF too high?
Supernus Pharmaceuticals' current EV-to-FCF of 127.79 is 760% above median its 10-year median of 14.86. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 128.24. The Drug Manufacturers industry median EV-to-FCF is 21.29. Supernus Pharmaceuticals' value of 127.79 is 500.2% above this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #496 out of 561 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' EV-to-FCF compare to RGC and BCRX?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #496 out of 561 companies for EV-to-FCF. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 21.29. Supernus Pharmaceuticals' value of 127.79 is 500.2% above this benchmark. Historically, Supernus Pharmaceuticals' own EV-to-FCF has ranged from 6.17 to 128.24 over the past decade. While the company's 10-year median is 14.86 vs. the industry median of 21.29, Supernus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.29, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current EV-to-FCF of 127.79 is 500.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current EV-to-FCF is 127.79, which is 760% above median its own 10-year median of 14.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Fairly Valued. The stock's GF Value™ is $43.43, compared to a current price of $47.95 — trading 10.4% above its estimated fair value. The current EV-to-FCF is 127.79, which is 760% above median its 10-year median of 14.86 and 500.2% above the Drug Manufacturers industry median of 21.29. Supernus Pharmaceuticals' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current EV-to-FCF is 127.79 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $47.95 is trading 10.4% above its estimated GF Value™ of $43.43.
GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0LB2:
EV-to-FCF: 127.79 (760% above median its 10-year median of 14.86)
GF Value™: $43.43 vs. price of $47.95 (10.4% above fair value)
Industry Position: 500.2% above the Drug Manufacturers median (#496 of 561)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score
Get the complete analysis for LTS:0LB2
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
